Tonix Secures Fibromyalgia Approval - What Investors Should Know

Group 1 - Tonix Pharmaceuticals (NASDAQ: TNXP) shares experienced a decline of nearly 15% during the day but rebounded with an increase of nearly 18% in post-market trading [1] - The Haggerston BioHealth investing group offers insights for both novice and experienced biotech investors, including catalysts to monitor and buy/sell ratings [1] - The group provides comprehensive financial analyses, including product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for major pharmaceutical companies [1] Group 2 - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma sectors [1]